Inhibitory Effect of Aqueous Extracts from Marine Sponges on the Activity and Expression of Gelatinases A (MMP-2) and B (MMP-9) in Rat Astrocyte Cultures

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Di Bari, Gaetano ^a   Gentile, Eugenia ^a   Latronico, Tiziana ^a   Corriero, Giuseppe ^a   Fasano, Anna ^a   Marzano, Carlotta Nonnis ^a   Liuzzi, Grazia Maria ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NATURAL PRODUCT; DRUG MIXTURE; GELATINASE; LIPOPOLYSACCHARIDE; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; SEA WATER; WATER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTE CULTURE; BIOLOGICAL ACTIVITY; CELL ACTIVATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MARINE SPECIES; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPONGE (PORIFERA); TETHYA AURANTIUM; TETHYA CITRINA; ZYMOGRAPHY; ANIMAL; CELL CULTURE; CELL DEATH; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG MIXTURE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; MEDITERRANEAN SEA; METABOLISM; PHARMACOLOGY;

RATTUS; TETHYA AURANTIUM;

ANIMALS; ASTROCYTES; CELL DEATH; CELL SURVIVAL; CELLS, CULTURED; COMPLEX MIXTURES; GELATINASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; LIPOPOLYSACCHARIDES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; MEDITERRANEAN SEA; PORIFERA; RATS; RNA, MESSENGER; SEAWATER; WATER;

EID: 84936797757     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129322     Document Type: Article

References (44)

1. Visse R, Nagase R (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Circ Res 92: 827-839. PMID: 12730128
2. Allan JA, Docherty AJ, Barker PJ, Huskisson NS, Reynolds JJ, et al. (1995) Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem J 309: 299-306. PMID: 7619071
3. Sang QX, Jin YH, Newcomer RG, Monroe SC, Fang XX, et al. (2006) Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases. Curr Top Med Chem 6: 289-316. PMID: 16611144
4. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinase in cancer progression. Nat Rev Cancer 2: 161-174. PMID: 11990853
5. Mastroianni CM, Liuzzi GM (2007) Matrix metalloproteinase dysregulation in HIV infection: implications for therapeutic strategies. Trends Mol Med 13: 449-459. PMID: 18029231
6. Yong VW, Power C, Forsyth P, Edwards DR (2001) Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2: 502-511. PMID: 11433375
7. Campbell IL, Pagenstecher A (1999) Matrix metalloproteinases and their inhibitors in the nervous system: the good, the bad and the enigmatic. Trends Neurosci 22: 285-287. PMID: 10484748
8. Rosenberg GA (2002) Matrix metalloproteinases in neuroinflammation. Glia 39: 279-291. PMID: 12203394
9. Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387-2392. PMID: 11923519
10. Overall CM, Lopez-Otin C (2002) Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2: 657-672. PMID: 12209155
11. Hu JL, Van den Steen PE, Sang QX, Opdenakker G (2007) Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 6: 480-498. PMID: 17541420
12. Pavlaki M, Zucker S (2003) Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 22: 177-203. PMID: 12784996
13. Skiles JW, Gonnella NC, Jeng AY (2004) The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. Curr Med Chem 11: 2911-2977. PMID: 15544483
14. Liuzzi GM, Latronico T, Fasano A, Carlone G, Riccio P (2004) Interferon-beta inhibits the expression of metalloproteinases in rat glial cell culture: implications for multiple sclerosis pathogenesis and treatment. Mult Scler 10: 290-297. PMID: 15222694
15. Liuzzi GM, Mastroianni CM, Latronico T, Mengoni F, Fasano A, et al. (2004) Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia. Brain 127: 398-407. PMID: 14662518
16. Latronico T, Liuzzi GM, Riccio P, Lichtner M, Mengoni F, et al. (2007) Antiretroviral therapy inhibits matrix metalloproteinase-9 from blood mononuclear cells of HIV-infected patients. AIDS 21: 677-684. PMID: 17413688
17. Gramegna P, Latronico T, Branà MT, Di Bari G, Mengoni F, et al. (2011) In vitro downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: Therapeutic Implication for HIV Brain Infection. PLoS ONE 6: e28499. doi: 10.1371/journal.pone.0028499 PMID: 22174822
18. Liuzzi GM, Latronico T, Rossano R, Viggiani S, Fasano A, et al. (2007) Inhibitory effect of polyunsaturated fatty acids on MMP-9 release from microglial cells-implications for complementary multiple sclerosis treatment. Neurochem Res 32: 2184-2193. PMID: 17624613
19. Liuzzi GM, Latronico T, Branà MT, Gramegna P, Coniglio MG, et al. (2011) Structure-dependent inhibition of gelatinases by dietary antioxidants in rat astrocytes and sera of multiple sclerosis patients. Neurochem Res 36: 517-527.
20. Zhang C, Kim SK (2009) Matrix metalloproteinase inhibitors (MMPIs) from marine natural products: the current situation and future prospects. Mar Drugs 7: 71-84. doi: 10.3390/md7020071 PMID: 19597572
21. Blunt JW, Copp BR, Keyzers RA, Munro MH, Prinsep MR (2014) Marine natural products. Nat Prod Rep 31: 160-258. doi: 10.1039/c3np70117d PMID: 24389707
22. Leal MC, Puga J, Serôdio J, Gomes NCM, Calado R (2012) Trends in the Discovery of New Marine Natural Products from Invertebrates over the Last Two Decades-Where and What Are We Bioprospecting? PLoS ONE 7: e30580. doi: 10.1371/journal.pone.0030580 PMID: 22276216
23. Fujita M, Nakao Y, Matsunaga S, Seiki M, Itoh Y, et al. (2003) Ageladine A: an antiangiogenicmatrixmetalloproteinase inhibitor from the marine sponge Agelas nakamurai. J Am Chem Soc 125: 15700-15701. PMID: 14677933
24. Fujita M, Nakao Y, Matsunaga S, Seiki M, Itoh Y, et al. (2001) Ancorinosides B-D, inhibitors of membrane type 1 matrix metalloproteinase (MT1-MMP), from the marine sponge Penares sollasi Thiele. Tetrahedron 57: 1229-1234.
25. Rodríguez-Nieto S, González-Iriarte M, Carmona R, Muñoz-Chápuli R, Medina MA, et al. (2002) Antiangiogenic activity of aeroplysinin-1, a brominated compound isolated from a marine sponge. Faseb J 16: 261-263. PMID: 11772945
26. Di Bari G, Gentile E, Latronico T, Corriero G, Fasano A, et al. (2014) Comparative analysis of protein profiles of aqueous extracts from marine sponges and assessment of cytotoxicity on different mammalian cell types. Environ Tox Pharm 38: 1007-1015.
27. Latronico T, Branà MT, Gramegna P, Fasano A, Di Bari G, et al. (2013) Inhibition of myelin-cleaving proteolytic activities by interferon-beta in rat astrocyte cultures. Comparative analysis between gelatinases and calpain-II. PLoS ONE 8: e49656. doi: 10.1371/journal.pone.0049656 PMID: 23390485
28. Lee WJ, Shin CY, Yoo BK, Ryu JR, Choi EY, et al. (2003) Induction of matrix metalloproteinase-9 (MMP-9) in lipopolysaccharide-stimulated primary astrocytes is mediated by extracellular signal-regulated protein kinase 1/2 (Erk1/2). Glia 41: 15-24. PMID: 12465042
29. Cardone F, Gaino E, Corriero G (2010) The budding process in Tethya citrina Sara & Melone (Porifera, Demospongiae) and the incidence of post-buds in sponge population maintenance. J Exp Mar Biol Ecol 389: 93-100.
30. Bradford MA (1976) Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254. PMID: 942051
31. Latronico T, Branà MT, Merra E, Fasano A, Di Bari G, et al. (2013) Impact of manganese neurotoxicity on MMP-9 production and superoxide dismutase activity in rat primary astrocytes. Effect of resveratrol and therapeutical implications for the treatment of CNS diseases.Toxicol Sci 135: 218-228. doi: 10.1093/toxsci/kft146 PMID: 23811825
32. Heussen C, Dowdle EB (1980) Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 102: 196-202. PMID: 7188842
33. Sipkema D, Franssen MC, Osinga R, Tramper J, Wijffels RH (2005) Marine sponges as pharmacy. Mar Biotechnol 7: 142-162. PMID: 15776313
34. Rosenberg GA (2009) Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 8: 205-216. doi: 10.1016/S1474-4422(09)70016-X PMID: 19161911
35. Malemud CJ (2006) Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 11: 1696-1701. PMID: 16368548
36. Mannello F (2006) Natural bio-drugs as matrix metalloproteinase inhibitors: new perspectives on the horizon? Recent Pat Anticancer Drug Discov 1: 91-103. PMID: 18221029
37. Bélanger M, Magistretti PJ (2009) The role of astroglia in neuroprotection. Dialogues Clin Neurosci 11: 281-295. PMID: 19877496
38. Lødemel JB, Egge-Jacobsen W, Olsen RL (2004) Detection of TIMP-2-like protein in Atlantic cod (Gadus morhua) muscle using two-dimensional real-time reverse zymography. Comp Biochem Physiol 139: 253-259. PMID: 15465672
39. Koopmans M, Martens D, Wijffels RH (2009) Towards Commercial Production of Sponge Medicines. Mar Drugs 7: 787-802. doi: 10.3390/md7040787 PMID: 20098610
40. Munro MHG, Blunt JW, Dumdei EJ, Hickford SH, Lill RE, et al. (1999) The discovery and development of marine compounds with pharmaceutical potential. J Biotechnol 70: 15-25. PMID: 10412202
41. Newman DJ, Cragg GM (2004) Marine Natural Products and Related Compounds in Clinical and Advanced Preclinical Trials. J Nat Prod 67: 1216-1238. PMID: 15332835
42. Duckworth AR, Battershill CN (2003) Developing farming structures for production of biologically active sponge metabolites. Aquaculture 217: 139-156.
43. Duckworth AR, Battershill CN (2003) Sponge aquaculture for the production of biologically active metabolites: The influence of farming protocols and environment. Aquaculture 221: 311-329.
44. Di Bari G, Cardone F, Gaino E, Liuzzi GM, Nonnis Marzano C, et al. (2015) Biological variations in a long-term ex situ cultivation: a Mediterranean demosponge as model system. Mediterr Mar Science 16: 73-81.